|
As part of heartflow's quality monitoring process, we identified a potential false negative.(b)(4): the investigation identified a potential false negative in the lcx region; after the initial analysis was delivered, a second analysis completed as part of ongoing quality review resulted in a decrease in the ffrct value from 0.87 to 0.67 in the lcx region.While heartflow has identified this issue, the physician has not provided feedback, nor indicated a safety event with the patient.
|